Evidence map›Paper›PMID 41294856›Full record

ReviewCells2025

Improvement of Treg Selectivity and Stability for Diabetes Mellitus Type 1 Treatment: Complex Approach for Perspective Technologies.

Andrei A Riabinin, Dmitry D Zhdanov, Varvara G Blinova, Alena A Permyakova, Alina A Stulova, Lyubov A Rzhanova, Sofya Y Nikitochkina, Elena I Morgun, Ekaterina A Vorotelyak

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andrei A RiabininKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.ORCID 0000-0002-7337-1166
Dmitry D ZhdanovKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.ORCID 0000-0003-4753-7588
Varvara G BlinovaKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.ORCID 0000-0002-3290-9839
Alena A PermyakovaKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.
Alina A StulovaDepartment of Histology, Cytology and Embryology, People's Friendship University of Russia Named After Patrice Lumumba (RUDN University), 6 Miklukho-Maklaya Street, Moscow 117198, Russia.
Lyubov A RzhanovaKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.ORCID 0000-0003-4082-7662
Sofya Y NikitochkinaKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.
Elena I MorgunKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.
Ekaterina A VorotelyakKoltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.ORCID 0000-0001-5405-0212

Funding

Ministry of Science and Higher Education of the Russian Federation the Federal Scientific-technical programme for genetic technologies development for 2019-2030, agreement N◦ 075-15-2025-464 from 29.05.2025 with the Ministry of Science and Higher Education of the Russian Federation
6 · The paper itself

Abstract

The adoptive transfer of Tregs is a promising immunotherapeutic strategy for type 1 diabetes mellitus (T1D). A key focus in this field is the creation of antigen-specific CAR-Tregs targeted against pancreatic islet antigens. However, the efficacy of such therapies is potentially limited by the instability of the Treg phenotype in the inflammatory conditions of T1D. This review discusses molecular approaches to overcome this limitation. These include the genetic engineering of cytokine signaling pathways (IL2, IL33/ST2, and IL35) and the cAMP cascade, the management of FOXP3 splicing to ensure stable expression of concrete splice variants, and the use of epigenetic mechanisms to promote a durable Treg identity.

Indexed as

Diabetes Mellitus, Type 1T-Lymphocytes, RegulatoryAnimalsCytokinesHumansCytokinesalternative splicingdiabetes mellitus type 1epigenetic modificationsgenetic modificationsregulatory T cells

Identifiers

PMID41294856
PMCPMC12650914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.